Rxcurve
HCPCS J7171 · per 10 UNITS

Inj, adzynma, 10 iu

Products billed under this code include Adzynma.

Payment limit per 10 UNITS, by effective quarter, 3Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J7171

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Adzynma Takeda Pharmaceuticals America, Inc. 64764-0140-05 1 $36.378
Adzynma Takeda Pharmaceuticals America, Inc. 64764-0145-05 1 $36.378

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $36.378 +$0.164 10 UNITS Inj, adzynma, 10 iu v1, posted September 17, 2026
3Q26 $36.214 +$0.638 10 UNITS Inj, adzynma, 10 iu v1, posted September 15, 2026
2Q26 $35.576 +$0.098 10 UNITS Inj, adzynma, 10 iu v1, posted September 15, 2026
1Q26 $35.478 −$0.109 10 UNITS Inj, adzynma, 10 iu v1, posted September 15, 2026
4Q25 $35.587 +$0.002 10 UNITS Inj, adzynma, 10 iu v1, posted September 8, 2026
3Q25 $35.585 +$1.069 10 UNITS Inj, adzynma, 10 iu v1, posted March 10, 2026
2Q25 $34.516 −$0.055 10 UNITS Inj, adzynma, 10 iu v1, posted March 10, 2026
1Q25 $34.571 −$0.026 10 UNITS Inj, adzynma, 10 iu v1, posted December 19, 2025
4Q24 $34.597 −$0.082 10 UNITS Inj, adzynma, 10 iu v1, posted June 11, 2025
3Q24 $34.679 – 10 UNITS Inj, adzynma, 10 iu v1, posted June 11, 2025

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files